4-溴-2-氯苯磺胺 | 351003-59-3

• 物质功能分类: 有机原料 - 氨基化合物 - 酰胺类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-氯苯磺胺
• 中文别名: 4-溴-2-氯苯磺酰胺
• 英文名称: 2-chloro-4-bromobenzenesulfonamide
• 英文别名: 4-bromo-2-chlorobenzenesulfonamide；2-chloro-4-bromo-benzenesulphonamide；4-bromo-2-chloro-benzenesulfonamide
• CAS: 351003-59-3
• 化学式: C₆H₅BrClNO₂S
• mdl: MFCD03427209
• 分子量: 270.534
• InChiKey: BFZLQNCZBMUSRS-UHFFFAOYSA-N

物化性质

• 熔点：
  172-176 °C(lit.)
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37,S39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2935009090
• 包装等级：
  I

SDS

Name:	4-Bromo-2-chlorobenzenesulfonamide Material Safety Data Sheet
Synonym:	None Known
CAS:	351003-59-3

Section 1 - Chemical Product MSDS Name:4-Bromo-2-chlorobenzenesulfonamide Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
351003-59-3	4-Bromo-2-chlorobenzenesulfonamide	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled. Can produce delayed pulmonary edema.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 351003-59-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white to almost white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 172 - 178 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5BrClNO2S
Molecular Weight: 270.53

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 351003-59-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-2-chlorobenzenesulfonamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 351003-59-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 351003-59-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 351003-59-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

4-溴-2-氯苯磺胺是一种氨基化合物，可作为医药中间体使用。

反应信息

• 作为反应物：
  描述：

  4-溴-2-氯苯磺胺 在 bis-triphenylphosphine-palladium(II) chloride copper(l) iodide 、 硫酸 作用下， 以 乙腈 为溶剂， 反应 1.17h， 生成 4,N-diacetyl-2-chloro-benzenesulfonamide
  参考文献：
  名称：

  [EN] MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY
  [FR] DÉRIVÉS DE MALONAMIDE PRÉSENTANT UNE ACTIVITÉ ANTITHROMBOTIQUE

  摘要：

  本发明涉及式(I)的化合物。式(I)的化合物是有价值的药理活性化合物。它们表现出强大的抗血栓作用，例如适用于治疗和预防心血管疾病，如血栓栓塞疾病或再狭窄。它们是血液凝块酶的抑制剂，特别是因子VIla，并且通常可应用于因子VIla的不良活性存在或因子VIla的抑制而打算治愈或预防的情况。此外，该发明还涉及制备式(I)化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物制剂。

  公开号：

  WO2009007015A1
• 作为产物：
  描述：

  4-溴苯磺酰胺 在 N-氯代丁二酰亚胺 、 三氟甲磺酸 、 palladium diacetate 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 3.5h， 以35%的产率得到4-溴-2-氯苯磺胺
  参考文献：
  名称：

  区域和化学选择性C ？弱配位的H氯化/缺电子芳烃的溴化和相对方向基团能力的研究

  摘要：

  都是相对的：已经开发了一种实用而有效的Pd II催化的区域和化学选择性氯化/溴化反应，可轻松合成各种芳族氯化物。该反应显示出优异的反应活性，良好的官能团耐受性和高收率。进行了一项初步研究，以评估各种功能的相对指导能力。

  DOI：

  10.1002/anie.201300176

文献信息

• [EN] NLRP MODULATORS<br/>[FR] MODULATEURS DE NLRP
  申请人：NOVARTIS INFLAMMASOME RES INC

  公开号：WO2020010140A1

  公开（公告）日：2020-01-09

  In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

  在一个方面，公式AA的化合物或其药用可接受盐被描述：或其药用可接受盐，其中在公式A中显示的变量可以如本文中的任何地方所定义。
• Design, Synthesis, and <i>in vitro</i> Evaluation of Tubulin‐Targeting Dibenzothiazines with Antiproliferative Activity as a Novel Heterocycle Building Block
  作者：Walter D. Guerra、Daniel Lucena‐Agell、Rafael Hortigüela、Roberto A. Rossi、J. Fernando Díaz、José M. Padrón、Silvia M. Barolo

  DOI：10.1002/cmdc.202100383

  日期：2021.10.6

  series of free NH and N-substituted dibenzonthiazines with potential anti-tumor activity from N-aryl-benzenesulfonamides. A biological test of synthesized compounds (59 samples) was performed in vitro measuring their antiproliferative activity against a panel of six human solid tumor cell lines and its tubulin inhibitory activity. We identified 6-(phenylsulfonyl)-6H-dibenzo[c,e][1,2]thiazine 5,5-dioxide

  我们从N-芳基苯磺酰胺中制备了一系列具有潜在抗肿瘤活性的游离 NH 和N-取代的二苯并噻嗪。在体外对合成的化合物（59 个样品）进行了生物学测试，测量了它们对一组六种人类实体肿瘤细胞系的抗增殖活性及其微管蛋白抑制活性。我们鉴定了 6-(苯磺酰基)-6 H-二苯并[ c , e ][1,2]噻嗪 5,5-二氧化物和 6-甲苯磺酰基-6 H-二苯并 [ c , e][1,2]噻嗪 5,5-二氧化物是具有良好活性值的最佳化合物（总体范围为 2–5.4 μM）。在此，我们报告了二苯并噻嗪核心作为具有抗增殖活性的新型构件，针对微管蛋白动力学。
• Rh(II)-Catalyzed Intermolecular Oxidative Sulfamidation of Aldehydes:  A Mild Efficient Synthesis of <i>N</i>-Sulfonylcarboxamides
  作者：Johann Chan、Kyle D. Baucom、Jerry A. Murry

  DOI：10.1021/ja073872a

  日期：2007.11.1

  Rh(II)-catalyzed oxidative coupling of aldehydes and sulfonamides has been developed to provide N-sulfonylcarboxamides in one step. A variety of sulfonamides were found to react with aromatic and aliphatic aldehydes to afford the desired products in good to excellent yields. Mechanistic data, including kinetic isotope effect experiments, suggest that the transformation proceeds through a concerted

  已经开发了 Rh(II) 催化的醛和磺酰胺的氧化偶联，以一步提供 N-磺酰甲酰胺。发现多种磺酰胺可与芳香族和脂肪族醛反应以良好至极好的收率提供所需产物。机械数据，包括动力学同位素效应实验，表明转化是通过协调的异步氮烯插入到醛氢中来进行的。
• [EN] SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS<br/>[FR] ARYLCYCLOPROPYLACETAMIDES SUBSTITUES SERVANT D'ACTIVATEURS DE GLUCOKINASE
  申请人：LILLY CO ELI

  公开号：WO2004063179A1

  公开（公告）日：2004-07-29

  According to the present invention there is provided a compounds of formula (I): and pharmaceutically acceptable salts thereof.

  根据本发明提供了以下式(I)的化合物及其药用可接受的盐。
• [EN] INDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'INDAZOLE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013130855A1

  公开（公告）日：2013-09-06

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.

  公开了Formula 1的化合物及其药用盐，其中R1、R2、R3、R4、R5和R6在规范中有定义。本公开还涉及制备Formula 1化合物的材料和方法，含有这些化合物的药物组合物，以及它们用于治疗肥胖和与MetAP2相关的疾病、紊乱和症状的用途。